Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: Final results of the Toronto phase II trial

Ronald L. Burkes, Frances A. Shepherd, Martin E. Blackstein, Melvin E. Goldberg, Paul F. Waters, G. Alexander Patterson, Thomas Todd, F. Griffith Pearson, Donald Jones, Samina Farooq, John McGlaughlin, Robert J. Ginsberg

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

This is a phase II study to assess the role of induction chemotherapy in the management of stage IIIA non-small-cell lung cancer (NSCLC). We are now reporting the long-term follow-up of the Toronto phase II trial. Sixty five patients with mediastinoscopy proven stage IIIA NSCLC received two cycles of preoperative MVP or VLB/P followed by thoracotomy followed by two further courses of chemotherapy. The overall response rate was 67.7% with three complete and 41 partial responders. Forty seven patients went on to thoracotomy with 35 complete resections. Pathologically 4.6% of patients had no tumour remaining. There were three postop deaths as well as five chemotherapy related deaths. Of the 35 patients completely resected 19 have recurred including eight in brain. The median survival for the entire 65 patients is 18.6 months with a 1 year survival of 66%, 5 year survival of 29% and a 10 year survival of 22%. The long-term survival of induction chemotherapy is maintained. The high incidence of brain recurrences warrants assessment of the role of prophylactic cranial radiation. The role of surgery for stage IIIA NSCLC following induction chemotherapy awaits further study.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalLung Cancer
Volume47
Issue number1
DOIs
StatePublished - Jan 2005

Keywords

  • Induction chemotherapy for stage IIIA NSCLC

Fingerprint

Dive into the research topics of 'Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: Final results of the Toronto phase II trial'. Together they form a unique fingerprint.

Cite this